Vast is a preclinical biotechnology company focused on treating the world’s most challenging drug-resistant microbial infections that represent one of the greatest threats to global health, food security, and economic development.
Vast’s patented technology gives us the unique ability to harness the unmatched antimicrobial activity of nitric oxide. This endogenously produced reactive compound plays a vital role in the natural immune system response to microbial pathogens. Taking cues from human physiology, our nitric oxide based “antibiotic alternative” compounds are not susceptible to antimicrobial resistance mechanisms common to traditional antibiotics.
This technology redefines broad-spectrum antimicrobial capability with demonstrated in vitro activity and high potency against a wide range of infectious bacteria and viruses, including inhibiting viral replications of SARS-CoV-2, the human coronavirus that causes COVID-19.